P-gp and MRP1 Expression in Parathyroid Tumors Related to Histology, Weight and ^99 mTc-Sestamibi Imaging Results

Abstract

Objective: P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) are membrane efflux pumps that may have a role in the kinetics of ^99mTc-sestamibi (MIBI) in parathyroid tumors. P-gp and MRP1 expression in parathyroid tumors was studied and related to histology, weight and pre- and intraoperative MIBI imaging results.

Design: Patient cohort study

Setting: Tertiary referral center

Patients: Thirty-three patients underwent radioguided parathyroidectomy for primary or secondary hyperparathyroidism.

Main outcome measures: P-gp and MRP1 expression.

Methods: Dual-phase ^99mTc-MIBI scintigraphy and SPECT results were compared to the surgical findings. Radioactivity and weight of resected parathyroid tumors were measured. Intraoperative radioactivity measurements were decay corrected. After routine histology immunohistochemistry was performed using C494 monoclonal antibodies to P-gp and MRP1r1 to MRP1. P-gp and MRP1 expression were scored covering both distribution of positivity and degree of immunostaining semi quantitatively.

Results: P-gp and MRP1 staining was observed in 97% and 43% of the glands respectively. P-gp staining was positive in 91% (21/23) of the adenomas and in all 36 hyperplastic glands. MRP1 staining was positive in 22% (5/23) of the adenomas and in 61% (22/36) of the hyperplastic glands. P-gp or MRP1 expression did not correlate with preoperative ^99mTc-MIBI imaging or intraoperative radioactivity. Parathyroid weight was associated with preoperative MIBI imaging results and MIBI uptake measured during surgery.

Conclusion: P-gp and MRP1 expression did not correlate with ^99mTc-MIBI uptake in parathyroid tumors. Parathyroid weight remains the major known factor influencing ^99mTc-MIBI uptake.

Key words

hypoparathyroidism - insufficiencies - hyperparathyroidism - Pgp

References

• 1 Giordano A, Rubello D, Casara D. New trends in parathyroid scintigraphy.  Eur J Nucl Med. 2001;  28 1409-1420
• 2 Denham DW, Norman J. Cost-effectiveness of preoperative sestamibi scan for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure.  J Am Coll Surg. 1998;  186 293-305
• 3 Pinero A, Rodriguez JM, Ortiz S. et al . Relation of biochemical, cytologic, and morphologic parameters to the result of gammagraphy with technetium 99m sestamibi in primary hyperparathyroidism.  Otolaryngol Head Neck Surg. 2000;  122 851-855
• 4 Pons F, Torregrosa JV, Vidal-Sicart S. et al . Preoperative parathyroid gland localization with technetium-99m sestamibi in secondary hyperparathyroidism.  Eur J Nucl Med. 1997;  24 1494-1498
• 5 Olaizola I, Zingraff J, Heuguerot C. et al . [c(99 m)Tc]-sestamibi parathyroid scintigraphy in chronic haemodialysis patients: static and dynamic explorations.  Nephrol Dial Transplant. 2000;  15 1201-1206
• 6 Piga M, Bolasco P, Satta L. et al . Double phase parathyroid technetium-99m-MIBI scintigraphy to identify functional autonomy in secondary hyperparathyroidism.  J Nucl Med. 1996;  37 565-569
• 7 Wu HS, Liu YC, Kao A. et al . Using technetium 99m tetrofosmin parathyroid imaging to detect parathyroid adenoma and its relation to P-glycoprotein expression.  Surgery. 2002;  132 456-460
• 8 Kao A, Shiau YC, Tsai SC. et al . Technetium-99m methoxyisobutylisonitrile imaging for parathyroid adenoma: relationship to P-glycoprotein or multidrug resistance-related protein expression.  Eur J Nucl Med. 2002;  29 1012-1015
• 9 Grzela T, Chudzinski W, Lazarczyk M. et al . Persisted/recurrent hyperparathyroidism associated with development of multidrug resistance phenotype and proliferation of parathyroid transplants.  Int J Mol Med. 2004;  14 595-599
• 10 Hendrikse NH, Franssen EJ, van der Graaf WT. et al . Visualization of multidrug resistance in vivo.  Eur J Nucl Med. 1999;  26 283-293
• 11 Chen CC, Meadows B, Regis J. et al . Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi.  Clin Cancer Res. 1997;  3 545-552
• 12 Luker GD, Fracasso PM, Dobkin J. et al . Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.  J Nucl Med. 1997;  38 369-372
• 13 Shiau YC, Tsai SC, Wang JJ. et al . Detecting parathyroid adenoma using technetium-99m tetrofosmin: comparison with P-glycoprotein and multidrug resistance related protein expression – a preliminary report.  Nucl Med Biol. 2002;  29 339-344
• 14 Murphy C, Norman J. The 20% rule: a simple, instantaneous radioactivity measurement defines cure and allows elimination of frozen sections and hormone assays during parathyroidectomy.  Surgery. 1999;  126 1023-1028
• 15 LiVolsi VA, Hamilton R. Intraoperative assessment of parathyroid gland pathology. A common view from the surgeon and the pathologist.  Am J Clin Pathol. 1994;  102 365-373
• 16 Johnson SJ, Sheffield EA, MacNicol AM. Best practice no 183. Examination of parathyroid gland specimens.  J Clin Pathol. 2005;  58 338-342
• 17 Bart J, Hollema H, Groen HJ. et al . The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours.  Eur J Cancer. 2004;  40 2064-2070
• 18 Flens MJ, Izquierdo MA, Scheffer GL. et al . Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies.  Cancer Res. 1994;  54 4557-4563
• 19 Beck WT, Grogan TM, Willman CL. et al . Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.  Cancer Res. 1996;  56 3010-3020
• 20 Sun SS, Shiau YC, Lin CC. et al . Correlation between P-glycoprotein (P-gp) expression in parathyroid and Tc-99m MIBI parathyroid image findings.  Nucl Med Biol. 2001;  28 929-933
• 21 Huang WT. Size and P-glycoprotein expression limit 99mTc-tetrofosmin uptake in parathyroid adenomas.  Nucl Med Commun. 2002;  23 1001-1004
• 22 Coakley AJ, Kettle AG, Wells CP. et al . 99 Tcm sestamibi – a new agent for parathyroid imaging.  Nucl Med Commun. 1989;  10 791-794
• 23 Pons F, Torregrosa JV, Fuster D. Biological factors influencing parathyroid localization.  Nucl Med Commun. 2003;  24 121-124
• 24 Biertho LD, Kim C, Wu HS. et al . Relationship between sestamibi uptake, parathyroid hormone assay, and nuclear morphology in primary hyperparathyroidism.  J Am Coll Surg. 2004;  199 229-233
• 25 Melloul M, Paz A, Koren R. et al . 99mTc-MIBI scintigraphy of parathyroid adenomas and its relation to tumour size and oxyphil cell abundance.  Eur J Nucl Med. 2001;  28 209-213
• 26 Axiotis CA, Bani D, Bianchi S. et al . P-glycoprotein is expressed in parathyroid epithelium and is regulated by calcium.  Calcif Tissue Int. 1995;  56 170-174
• 27 Yamaguchi MDP, Yachiku MDP, Hashimoto MDP. et al . Relation between technetium 99 m-methoxyisobutylisonitrile accumulation and multidrug resistance protein in the parathyroid glands.  World J Surg. 2002;  26 29-34
• 28 Gupta Y, Ahmed R, Happerfield L. et al . P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism Br.  J Surg. 2007;  94 1491-1495
• 29 Ugur O, Bozkurt MF, Hamaloglu E. et al . Clinicopathologic and radiopharmacokinetic factors affecting gamma probe-guided parathyroidectomy.  Arch Surg. 2004;  139 1175-1179
• 30 Mitchell BK, Cornelius EA, Zoghbi S. et al . Mechanism of technetium 99m sestamibi parathyroid imaging and the possible role of p-glycoprotein.  Surgery. 1996;  120 1039-1045
• 31 Chudzinski W, Niderla J, Lasiecka Z. et al . P-glycoprotein expression influences the result of 99mTc-MIBI scintigraphy in tertiary hyperparathyroidism.  Int J Mol Med. 2005;  16 215-219
• 32 Bhatnagar A, Vezza PR, Bryan JA. et al . Technetium-99m-sestamibi parathyroid scintigraphy: effect of P-glycoprotein, histology and tumor size on detectability.  J Nucl Med. 1998;  39 1617-1620
• 33 Turgut B, Elagoz S, Erselcan T. et al . Preoperative localization of parathyroid adenomas with technetium-99m methoxyisobutylisonitrile imaging: relationship with P-glycoprotein expression, oxyphilic cell content, and tumoral tissue volume.  Cancer Biother Radiopharm. 2006;  21 579-590
• 34 Faneyte IF, Kristel PM, Vijver MJ van de. Determining MDR1/P-glycoprotein expression in breast cancer.  Int J Cancer. 2001;  93 114-122
• 35 Arbab AS, Ueki J, Koizumi K. et al . Effects of extracellular Na+and Ca2+ions and Ca2+channel modulators on the cell-associated activity of 99mTc-MIBI and 99mTc-tetrofosmin in tumour cells.  Nucl Med Commun. 2003;  24 155-166
• 36 Siddiqui A, Kerb R, Weale ME. et al . Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.  N Engl J Med. 2003;  348 1442-1448

Correspondence